ClinicalTrials.gg

Program

patritumab deruxtecan

Also written as “HER3-DXd”, “Patritumab deruxtecan” and “Patritumab Deruxtecan”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Esophageal Neoplasms · Melanoma · Neoplasms, led by 2 companies.

Furthest: phase 3, since Jul 2, 202517 company-led studies, 15 open or runningCo-development: Daiichi Sankyo and Merck, Oct 2023Next primary completion: May 9, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck99 open or runningphase 3since Jul 2, 2025Nov 14, 2019May 9, 2028phase 2 · NCT06445972
Daiichi Sankyo86 open or runningphase 3since Apr 15, 2022Nov 28, 2016Nov 19, 2030phase 2 · NCT06172478
  • Named in Merck’s own pipeline as patritumab deruxtecan (MK-1022), phase 3, as of Nov 2, 2026 (source).

Also a collaborator on its studies: AstraZeneca.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Nov 28, 2016.

  1. Dec 15, 2020Phase 1 study in Carcinoma, Non-Small-Cell LungDaiichi Sankyo · NCT04676477 · 246 enrolled · United States, Japan, South Korea and more
  2. Apr 15, 2022Phase 3 study in Nonsquamous Non-small Cell Lung CancerDaiichi Sankyo · NCT05338970 · 586 enrolled · United States, Australia, Austria and more
  3. Oct 19, 2023Merck develops it with Daiichi SankyoCo-developmentWorldwide except Japan, where Daiichi Sankyo keeps the rights · announced · Merck
  4. Dec 7, 2023Phase 2 study in MelanomaDaiichi Sankyo · NCT06172478 · 890 planned · United States, Australia, Belgium and more
  5. May 31, 2024Phase 2 study in Esophageal NeoplasmsMerck · NCT06445972 · 210 planned · United States, Brazil, Chile and more
  6. Jun 17, 2024Phase 2 study in Esophageal NeoplasmsMerck · NCT06469944 · 160 planned · United States, Brazil, Chile and more
  7. Sep 11, 2024Phase 2 study in Gastrointestinal NeoplasmsMerck · NCT06596694 · 180 enrolled · United States, Australia, Canada and more
  8. Nov 11, 2024Phase 2 study in Breast NeoplasmsMerck · NCT06686394 · 181 planned · United States, Canada, Israel and more
  9. Dec 11, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungMerck · NCT06731907 · 90 planned · United States, Chile, Greece and more
  10. Jan 21, 2025Phase 2 study in Breast NeoplasmsMerck · NCT06797635 · 372 planned · United States, South Korea, Spain and more
  11. Feb 27, 2025Phase 2 study in NeoplasmsMerck · NCT06941272 · 50 planned · United States, Australia, Belgium and more
  12. Jul 2, 2025Phase 3 study in Breast NeoplasmsMerck · NCT07060807 · 1,000 planned · United States, Argentina, Australia and more
  13. Jul 8, 2026Phase 2 study in Breast NeoplasmsDaiichi Sankyo · NCT07701941 · 220 planned · United States, Belgium, France and more
  14. Oct 21, 2026Primary completion moved from 2030-04-18 to 2032-08-02Date moved laterphase 2 · +27 months · NCT06686394
  15. Nov 17, 2026Primary completion moved from 2027-09-01 to 2030-11-19Date moved laterphase 2 · +39 months · NCT06172478

Ahead

  1. May 9, 2028Primary completion: phase 2 study in Esophageal NeoplasmsMerck · NCT06445972
  2. Dec 7, 2028Primary completion: phase 2 study in Gastrointestinal NeoplasmsMerck · NCT06596694
  3. Sep 12, 2029Primary completion: phase 2 study in Esophageal NeoplasmsMerck · NCT06469944
  4. Dec 31, 2029Primary completion: phase 2 study in Breast NeoplasmsMerck · NCT06797635

TargetBeta

“An antibody-drug conjugate (ADC) composed of patritumab, a monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3),linked to the topoisomerase I inhibitor DX 8951, a semisynthetic, water-soluble derivative of camptothecin, with potential antineoplastic activit…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of patritumab, a monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3),”NCIt, by rule
“Receptor tyrosine-protein kinase erbB-3 binding agent”ChEMBL 37, by rule

Other programs on ERBB3

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
beruzatatug pelitecanruleMediLink Therapeutics (Suzhou)phase 39
ruzaltatug rezetecanJiangsu HengRui Medicinephase 38
JSKN016ruleAlphamab Oncologyphase 35
SYS6023ruleCSPC Pharmaceutical Groupphase 22
Anti-HER3/Anti-MUC1 Bispecific Antibody-drug Conjugate DM002rulexadcera-biopharmaceutical-suzhou-co-ltdphase 21
Anti-HER3/Exatecan Antibody-drug Conjugate ENV-501rulehummingbird-biosciencephase 21
Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate AVZO-1418ruleavenzo-therapeutics-incphase 21
KHN922ruleChengdu Kanghong Pharmaceutical Groupphase 21
CS5007ruleCStone Pharmaceuticalsphase 11
JSKN016HCruleAlphamab Oncologyphase 11

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07701941Breast Neoplasms · United States, Belgium, France and more2RecruitingDaiichi SankyoJan 1, 2031220
NCT07060807Breast Neoplasms · United States, Argentina, Australia and more3RecruitingMerckJul 14, 20331,000
NCT06941272Neoplasms · United States, Australia, Belgium and more2RecruitingMerckDec 30, 203050
NCT06797635Breast Neoplasms · United States, South Korea, Spain and more2RecruitingMerckDec 31, 2029372
NCT06731907Carcinoma, Non-Small-Cell Lung · United States, Chile, Greece and more2RecruitingMerckMar 12, 203290
NCT06686394Breast Neoplasms · United States, Canada, Israel and more2RecruitingMerckAug 2, 2032181
NCT06596694Gastrointestinal Neoplasms · United States, Australia, Canada and more2Active, not recruitingMerckDec 7, 2028180
NCT06469944Esophageal Neoplasms · United States, Brazil, Chile and more2RecruitingMerckSep 12, 2029160
NCT06445972Esophageal Neoplasms · United States, Brazil, Chile and more2RecruitingMerckMay 9, 2028210
NCT06172478Melanoma · United States, Australia, Belgium and more2RecruitingDaiichi SankyoNov 19, 2030890
NCT05338970Nonsquamous Non-small Cell Lung Cancer · United States, Australia, Austria and more3Active, not recruitingDaiichi SankyoMay 31, 2024586
NCT04676477Carcinoma, Non-Small-Cell Lung · United States, Japan, South Korea and more1Active, not recruitingDaiichi SankyoJan 31, 2025246
NCT04619004Non-Small Cell Lung Cancer Metastatic · United States, Australia, Austria and more2Active, not recruitingDaiichi SankyoNov 21, 2022277
NCT04479436Colorectal Neoplasms · United States, Belgium, France and more2TerminatedDaiichi SankyoFeb 3, 202240
NCT04165070Carcinoma, Non-Small-Cell Lung · United States, Canada, Hungary and more2RecruitingMerckFeb 13, 2032450
NCT03260491Carcinoma, Non-Small-Cell Lung · United States, Japan, Netherlands and more1Active, not recruitingDaiichi SankyoDec 1, 2025312
NCT02980341Breast Neoplasms · United States, Japan2CompletedDaiichi SankyoAug 16, 2021182

How it is read

Names in the registry

  • “HER3-DXd”, 8 entries
  • “Patritumab deruxtecan”, 5 entries
  • “Patritumab Deruxtecan”, 5 entries
  • “Patritumab Deruxtecan (Fixed dose)”, 1 entry
  • “Patritumab Deruxtecan (Up-Titration)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.